Actelion accelerates immunology push with MS drug trial

Actelion, Europe's biggest biotechnology company, is accelerating its push into immunology with the launch of late-stage tests of a drug for multiple sclerosis. The Swiss group said on Thursday that it had initiated final Phase III development of ponesimod for relapsing multiple sclerosis and patients would be enrolled in a clinical trial imminently.

http://ift.tt/1yuACqs